Updated:
MorphoSys AG
MorphoSys AG was founded in 1992 as a spinout from the Max Planck Institute for Biochemistry in Martinsried, Germany, by Dr. Andreas Plückthun and Dr.
MorphoSys AG
MorphoSys AG was founded in 1992 as a spinout from the Max Planck Institute for Biochemistry in Martinsried, Germany, by Dr. Andreas Plückthun and Dr. Joachim Theis. The firm began by commercializing its human combinatorial antibody library (HuCAL) technology, which became the backbone of its partnering model with larger pharma companies. The company's strategy blends proprietary drug discovery with partnered development. Its lead asset, tafasitamab (sold as Monjuvi in the US, Minjuvi in Europe), received FDA approval in 2020 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). MorphoSys also built a pipeline that includes gantenerumab (partnered with Roche for Alzheimer's disease) and multiple preclinical candidates in oncology and inflammation. The firm operates labs and offices in Planegg, Munich, and Boston, Massachusetts. As of 2023, MorphoSys employed approximately 450 staff, with its US subsidiary (MorphoSys US Inc.) handling Monjuvi's commercialization. In February 2024, the company accepted a €2.7B all-cash acquisition offer from Novartis, structuring the deal to close in the first half of 2024. The acquisition valued MorphoSys at €68 per share, a 37% premium over its prior trading price. MorphoSys also operates a philanthropic foundation, MorphoSys Foundation, which supports health and science initiatives in the Munich area. MorphoSys's structural differentiator is its hybrid model: it functions like a discovery-stage biotechnology company with a validated commercial product, while maintaining a technology platform that generates licensing revenue from partners such as Roche, Janssen, and Novartis. This dual revenue stream — milestone payments from partners plus direct sales of Monjuvi — reduces the typical risk profile of a small-cap biotech. The Novartis acquisition, if completed, would integrate MorphoSys's pipeline into one of the world's largest pharma companies, dissolving the independent firm.
General information
Firm type
other
Year founded
1992
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Planegg
Corporate office
Planegg, Germany
Additional offices
Munich, Germany · Boston, United States
Principals
Dr. Jean-Paul Kress
Chief Executive Officer
Dr. Markus Enzelberger
Chief Scientific Officer
Dr. Malte Peters
Chief Development Officer
Sector focus
Frequently asked questions
What is MorphoSys's core technology platform?
MorphoSys's foundation is HuCAL (Human Combinatorial Antibody Library), a synthetic antibody library built from modular building blocks. The company later developed Ylanthia, a next-generation platform for generating fully human antibodies. These platforms have been used to discover over 100 antibodies, many partnered with large pharma.
What is Monjuvi (tafasitamab) and how is it commercialized?
Monjuvi is a CD19-targeting immunotherapy approved by the FDA in 2020 for relapsed or refractory diffuse large B-cell lymphoma. MorphoSys commercialized it in the US via its own sales force, then partnered with Incyte for ex-US rights (sold as Minjuvi). The drug generated approximately $93M in US sales in 2023 (per MorphoSys annual report, 2023).
Who are MorphoSys's key partners?
Major partners include Roche (gantenerumab for Alzheimer's, plus other antibodies), Janssen (part of Johnson & Johnson), Novartis (which is acquiring the company), and Incyte (co-promotion of tafasitamab outside the US). These partnerships provided discovery milestones and royalties.
What is the expected impact of the Novartis acquisition?
The €2.7B acquisition, announced February 2024, is expected to close in the first half of 2024 pending regulatory approvals. Novartis stated the deal would strengthen its oncology pipeline, particularly in hematology, and combine tafasitamab with its own portfolio (per Novartis press release, February 2024).
Does MorphoSys have a philanthropic arm?
Yes, the MorphoSys Foundation was established in 2001. It supports scientific research, education, and health initiatives in the Munich area. The foundation is separate from the corporate entity and operates with its own endowment from MorphoSys stock and donations.
What is MorphoSys's financial position as of late 2023?
Before the acquisition, MorphoSys reported cash and equivalents of around €400M as of September 2023. Revenue came primarily from Monjuvi sales and partner milestone payments. The company had not achieved profitability but had a strong cash runway (per MorphoSys Q3 2023 financial report).
How did the COVID-19 pandemic affect MorphoSys?
MorphoSys's antibody discovery platforms were used to identify SARS-CoV-2 antibodies under a collaboration with the University of Bonn. These efforts did not result in a marketed product but demonstrated the platform's versatility. The pandemic also slowed clinical trial enrollment for Monjuvi in 2020-2021.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: